Leukaemia

Researchers in Cambridge have pioneered the development of an innovative affinity maturation technique to generate high-affinity antibody against Arginase 2.

The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.  

The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland

Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.

A targeted combination treatment for patients with a specific type of blood cancer will soon be available on the NHS in Scotland.

A breast cancer drug and two blood cancer treatments have been recommended for use on the NHS in Scotland.

Patients living with a specific type of leukaemia will have access to a new immunotherapy treatment on the NHS in England.

Three cancer drugs have been approved for patients on the NHS in Scotland, including a drug for some patients with advanced liver cancer.

Patients with a specific type of leukaemia will not have access to a new treatment after it failed to win provisional recommendation for NHS use in England.

Two cancer immunotherapies have been reviewed for NHS use in Scotland as a treatment for some patients with aggressive blood cancer.